Latest Ratios: P/E Ratio -0.8x · EV/EBITDA N/A · ROE -139.8%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $404M | $431M | $74M | — | — | — | — | — | — |
| Enterprise Value | $281305 | $402M | $422M | $69M | — | — | — | — | — | — |
| P/E Ratio → | -0.79 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.54 | 339.13 | 99.62 | 75.35 | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -139.8% | -139.8% | -197.9% | -875.4% | -836.6% | -172.1% | -96.6% | -73.4% | -171.1% | -13.2% |
| ROA | -47.7% | -47.7% | -65.5% | -243.4% | -375.8% | -160.8% | -88.5% | -64.4% | -137.2% | -6.5% |
| ROIC | — | — | — | — | — | -1865.6% | -151.2% | -68.8% | -406.8% | — |
| ROCE | -204.5% | -204.5% | -215.5% | -640.1% | -758.5% | -170.1% | -96.6% | -73.4% | -223.8% | -13.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.49 | 1.49 | 0.02 | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.80 | -2.10 | -5.52 | — | -0.96 | -0.66 | -0.01 | -0.31 | -1.62 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -192.82 | -192.82 | -133.86 | — | -475.20 | — | — | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.22 | 1.22 | 1.72 | 1.17 | 0.22 | 13.78 | 24.92 | 0.08 | 10.75 | 1.68 |
| Quick Ratio | 1.22 | 1.22 | 1.72 | 1.17 | 0.22 | 13.78 | 24.92 | 0.08 | 10.75 | 1.68 |
| Cash Ratio | 1.14 | 1.14 | 1.66 | 1.11 | 0.17 | 12.88 | 24.68 | 0.02 | 9.64 | 1.56 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $1M | $775030 | $50620 | $10830 | $7727 | $4532 | $3083 | $2694 | $3055 |
Imminent dilutive financing risk
Based on reported financial data, Clearmind's P/B ratio of 2.54 reflects a market valuation detached from tangible book value, as investors assign value primarily to the potential of the MEAI molecule rather than current operational assets or any established revenue-generating capacity within the biotechnology sector.
The absence of P/E and EV/EBITDA multiples underscores the company's pre-revenue status, rendering traditional valuation metrics largely inapplicable. Investors appear to be pricing the firm as a high-risk option on clinical success, where the valuation is sensitive to regulatory milestones rather than fundamental earnings growth.
As reported in financial statements, the company's ROIC of -7.3% in 2026Q2 highlights a persistent inability to generate returns on invested capital, a trend consistent with the heavy R&D expenditure required to advance its synthetic molecule pipeline toward potential clinical trial applications.
The negative return profile suggests that capital is being consumed to fund research rather than to build a compounding asset base. Without a transition to a licensing model or commercial success, this trend of decaying returns on capital is likely to persist as the firm continues its cash-intensive development phase.
According to recent SEC filings, the current ratio of 4.79 in 2026Q2 provides a superficial appearance of liquidity, yet this metric is misleading given the company's lack of revenue and the high-velocity cash burn required to sustain its ongoing pre-clinical development and patent filing strategies.
The volatility in the current ratio, which swung from 1.22 in 2025Q4 to 4.79 in 2026Q2, suggests an unstable working capital position that is highly susceptible to the timing of equity raises. This liquidity profile warrants caution, as the firm remains entirely dependent on external capital markets to maintain operations.
As indicated by the financial data, the current ratio is the most commonly misapplied metric for Clearmind, as it obscures the firm's lack of operational cash flow and the reality that its current assets are being rapidly depleted to fund non-revenue-generating research and development activities.
Investors should instead focus on the monthly cash burn-to-runway ratio, which provides a more accurate assessment of the firm's survival horizon. Relying on the current ratio ignores the structural reality that the company lacks a self-sustaining business model, making traditional liquidity analysis insufficient for assessing long-term viability.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CMND stock.
Clearmind Medicine Inc.'s current P/E ratio is -0.8x. This places it at the 50th percentile of its historical range.
Clearmind Medicine Inc.'s return on equity (ROE) is -139.8%. The historical average is -123.4%.
Based on historical data, Clearmind Medicine Inc. is trading at a P/E of -0.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.